Detailed explanation of Olaparib specifications, dosage and price information

Olaparib is a PARP inhibitor, mainly used to treat a variety of solid tumors carrying BRCA mutations such as ovarian cancer, breast cancer, prostate cancer and pancreatic cancer. Its mechanism of action is to inhibit the activity of poly(ADP-ribose) polymerase (PARP) and block the DNA repair pathway of cancer cells, thereby inducing cancer cell death. At present, the main specifications of Lynparza on the domestic market are 150mg and 100mg tablets, of which 150mg*56 tablets are the most common. The medicine is an oral tablet, which needs to be swallowed whole. It is forbidden to break or chew it to ensure the stable release and absorption of the medicine.

In clinical treatment, the recommended dose of olaparib is usually 300mg (i.e. 150mg tablets 2 tablets) twice daily, with a total daily dose of 600mg. For some patients, if adverse reactions such as nausea, vomiting, fatigue or bone marrow suppression occur, the dose can be adjusted to 200mg twice a day according to the doctor's advice. At the same time, patients with moderately impaired renal function also need to reduce the dose appropriately. Lynparza can generally be taken after or before meals, but it is recommended to take the drug at a fixed time to maintain stable blood concentration. The course of treatment usually continues until the disease progresses or becomes intolerable. During this period, blood and liver and kidney functions need to be monitored regularly.

Olaparib has now been officially launched in mainland China and has been included in the national medical insurance directory. Patients can purchase it at large domestic hospital pharmacies or authorized pharmacies. Common specifications150mg*56The price of tablets is around RMB 4,000 to RMB 5,000, and the patient’s out-of-pocket payment ratio is significantly reduced after medical insurance reimbursement. Since medical insurance policies and reimbursement ratios vary slightly from place to place, it is recommended that patients consult the pharmacy of the hospital where they are treated for specific policies. Compared with the early import self-pay stage, the inclusion of Lynparza in medical insurance has greatly reduced the financial burden on patients, allowing more cancer patients to use this drug in a long-term and standardized manner.

In the international market, there are also multiple versions of Olaparib circulating. The higher-priced drugs abroad are European or American original drugs, while generic drugs from Bangladesh and Laos have attracted attention due to their high cost performance. The common specifications overseas are 150mg*120 tablets, and the price is about RMB 2,000, which is nearly half cheaper than the domestic original drug. The ingredients and efficacy of this type of generic drugs are basically the same as those of the original drugs. However, due to differences in channels and supervision, it is recommended that patients only obtain them through regular overseas pharmacies or medical institutions and use them under the guidance of a doctor. Overall, olaparib is an efficient and clinically proven targeted drug, both at home and abroad, and has become an important choice for maintenance treatment of various cancers.

Reference materials:https://www.drugs.com/